Univest
Univest
  • Markets
  • Bal Pharma Analyst Review 2027: Revenue Up 22% and Profit Doubles, but Debt Is Heavy

    • November 20, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Bal Pharma Analyst Review 2027: Revenue Up 22% and Profit Doubles, but Debt Is Heavy

    Bal Pharma, a Bengaluru-based maker of APIs and formulations, grew Q2 FY27 revenue 22% to ₹90 crore and nearly doubled profit to ₹1.43 crore. With no brokerage coverage, thin margins and debt above twice equity, we review the business, valuation and risks for 2027.

    read more